Shares of Mallinckrodt PLC (NYSE:MNK) have been assigned an average rating of “Hold” from the twenty-two brokerages that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $31.68.
Several analysts have commented on the stock. Barclays upped their target price on shares of Mallinckrodt from $12.00 to $20.00 and gave the company an “underweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Mallinckrodt from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research report on Wednesday. Canaccord Genuity set a $34.00 target price on shares of Mallinckrodt and gave the company a “hold” rating in a research report on Sunday, August 19th. B. Riley upped their target price on shares of Mallinckrodt from $15.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, June 28th. Finally, Stifel Nicolaus upped their target price on shares of Mallinckrodt from $15.00 to $18.00 and gave the company a “hold” rating in a research report on Monday, June 18th.
Several hedge funds have recently made changes to their positions in MNK. Victory Capital Management Inc. acquired a new position in shares of Mallinckrodt in the 1st quarter valued at $104,000. Financial Gravity Wealth Inc. acquired a new position in shares of Mallinckrodt in the 1st quarter valued at $182,000. Advisors Preferred LLC grew its holdings in shares of Mallinckrodt by 493.9% in the 2nd quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock valued at $196,000 after buying an additional 8,742 shares during the period. Balasa Dinverno & Foltz LLC acquired a new position in shares of Mallinckrodt in the 2nd quarter valued at $200,000. Finally, TLP Group LLC acquired a new position in shares of Mallinckrodt in the 1st quarter valued at $208,000.
Shares of Mallinckrodt stock opened at $29.23 on Friday. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 3.90, a price-to-earnings-growth ratio of 0.49 and a beta of 1.57. Mallinckrodt has a 52 week low of $11.65 and a 52 week high of $39.05. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.27 and a quick ratio of 2.06.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, August 7th. The company reported $1.78 EPS for the quarter, beating the consensus estimate of $1.48 by $0.30. The company had revenue of $631.70 million during the quarter, compared to analysts’ expectations of $621.15 million. Mallinckrodt had a net margin of 59.85% and a return on equity of 10.39%. sell-side analysts forecast that Mallinckrodt will post 6.7 EPS for the current year.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.